Remedica Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Remedica Ltd. - overview
Established
1980
Location
Limassol, -, Cyprus
Primary Industry
Pharmaceuticals
About
Founded in 1980 by Takis Pattichis and based in Limassol, Cyprus, Remedica Ltd. produces generic and over-the-counter pharmaceutical products and exports its products in more than 10 countries. In August 2016, Ascendis Health Limited acquired Remedica Ltd. for EUR 260 million.
As of 2021, the company employs more than 800 employees, has over 350 pharmaceutical products, and is led by its CEO Dr. Michael Neoptolemou. Remedica manufactures generic and over-the-counter pharmaceutical products such as antidepressants, antivirals, antibacterials, immunosuppressants, blocking agents, and anti-inflammatory tablets and capsules. The company has factories that produce pharmaceutical products for general use, penicillin derivatives, cefalosporins, and cancer treatment.
Current Investors
Ascendis Health Limited
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.remedica.eu
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Remedica Ltd. - timeline of key events
Remedica Ltd. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2020 | Jun 30, 2021 | Jun 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 55,560,254 | 60,085,116 | 69,855,942 | 31,586,292 | 71,831,774 | 86,624,422 | 95,330,528 | - | - | - |
| % Revenue Growth (YoY) | - | 8.1% | 16.3% | - | - | 20.6% | 10.1% | - | - | - |
| EBITDA (USD) | 11,995,838 | 10,898,823 | 17,771,604 | 4,855,395 | 21,369,608 | 27,334,130 | (1,150,158) | - | - | - |
| Operating Income (USD) | 9,066,253 | 7,648,874 | 13,836,364 | 2,854,919 | 21,382,801 | 27,600,035 | (1,183,939) | - | - | - |
| Operating Margin | 16.3% | 12.7% | 19.8% | 9.0% | 29.8% | 31.9% | (1.2%) | - | - | - |
| % EBITDA Margin | 21.6% | 18.1% | 25.4% | 15.4% | 29.7% | 31.6% | (1.2%) | - | - | - |
| NET Income (USD) | 7,680,307 | 7,921,174 | 13,087,735 | 2,211,499 | 20,648,934 | 26,813,614 | (2,494,256) | - | - | - |
| % Net Margin | 13.8% | 13.2% | 18.7% | 7.0% | 28.7% | 31.0% | (2.6%) | - | - | - |
Remedica Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LP Direct, Trade Sale | Completed | Remedica Ltd. | - | ||||||||
| Secondary Buyout | Completed | Remedica Ltd. | - | ||||||||
| Add-on | Completed | Remedica Ltd. | - |
Displaying 1 - 3 of 3
Remedica Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.